Connect with us

Headlines

Vision Council Unveils ‘Reimagination’ of Vision Expo

The next show is set for March 26-29.

mm

Published

on

ALEXANDRIA, VA –  The Vision Council announced that it is “reimagining” its signature trade show, the bi-annual Vision Expo, for 2020.

The council, together with co-owner of the Show Reed Exhibitions, “aims to mark a new era for Vision Expo with a laser-like focus on discovery, connection and experience,” according to a press release.

Along with refreshed branding, including redesigned logos and show tagline (“The Future, Clearly”), changes will first be seen at Vision Expo East 2020, set for the Javits Center in New York City March 26–29. Shaped by feedback from both exhibitors and attendees, the new concept “is anchored in the form of curated neighborhoods, optimizing the connection between sellers and buyers, as well as exhibit spaces with enhanced design creativity and interactive appeal,” according to the release.

“We are excited to invest in the growth and evolution of Vision Expo, and the industry at large,” said Ashley Mills, CEO of The Vision Council. “The show has always served as a discovery zone for innovative products and services, new technology and fashion trends, while simultaneously encouraging and challenging the industry. 2020 provides unique significance in leading us into a vibrant future and we know the reimagination of Vision Expo will present the optical industry with the perfect platform to make that happen.”

Vision Expo East 2020 will welcome the first-phase debut of three new distinct neighborhoods:

  • The River – Daring, design-driven artisanal products creating a show-within-a-show pavilion for select industry leaders. Exhibitors in The River include Thierry Lasry, Maybach, FACE A FACE/Kilsgaard, l.a. Eyeworks, Piero Massaro/Italiana Design, Pugnale, Linda Farrow, Rigards, Anna-Karin Karlsson, Gold & Wood, Kio Yamato, Kuboram, Jacques Marie Mage, Garrett Leight/Mr. Leight, Eyevan, La LOOP, Matsuda, BAARS, Christian Roth, Robert Marc and DITA. (Located in the River Pavilion on Level 4)
  • The Union – The ultimate shopping experience of boutique and premium independent brands including exclusive, hip and fashion-forward lifestyle brands. Sample exhibitors for The Union include Lafont, OGI, Jonathan Cate, and Etnia Barcelona. (Level 3)
  • The Springs – Incubator zone for emerging talent in eyewear design. Exhibitors in The Springs include Jean Philippe Joly, Komorebi Eyewear, Mondelliani Eyewear, Nina Mur, Turchin Eyerings, Dzmitry Samal and Stellis Eyeworks. (Level 3)

Additional neighborhoods are planned to debut at Vision Expo East 2021, including new identities for three other essential aspects of the show.

Advertisement

“In the last 10 years, the exhibitions industry has seen its share of disruption and evolution,” said Yancy Weinrich, chief operations officer of Reed Exhibitions. “We’re meeting the challenge head-on with our re-imagination of Vision Expo through visually exciting new neighborhoods, technology and digitally driven tools to enhance business and lead generation at the show, and education that will take our audiences to new levels in their practices and businesses.”

Furthermore, a fresh take to the show’s continuing education courses includes an accredited education area dedicated to seminars, workshops and presentations led by experts in practice management, business and marketing.

“Advancements in continuing education programs are also central to Vision Expo’s reimagined presence,” said Mark Dunbar, OD, FAAO, Education Advisory Board Co-Chairman. “Custom designed for Vision Expo by the Education Advisory Board, the 2020 Education program includes exclusive, never-before-seen clinical presentations staged for the first time ever at Vision Expo East. Organized by key content areas including glaucoma, posterior segment/retina, anterior segment/dry eye, surgical/co-management, and systemic disease and diabetes, clinical attendees will discover courses specifically developed to immerse them in the most cutting-edge developments for better patient care.”

More information about the Vision Expo can be found at east.visionexpo.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY KENMARK

Jump In — the Water’s Fine!

With a salute to summer’s shimmery, mermaid colors and warm weather-loving shades, Kenmark Eyewear celebrates this summer’s Aloha spirit with eyewear from Vera Wang, Kensie, Zac Posen and the Original Penguin Collection!

Promoted Headlines

Headlines

Biotech Firm Raises $30M for Eye Disease Therapies

It’s focusing on retinal and other ophthalmic maladies.

mm

Published

on

PARIS & FORT WORTH, TX — Eyevensys, a biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, has completed a $30 million funding round.

The company will use the funds to continue development of its clinical lead candidate — known as EYS606 — for the treatment of chronic non-infectious uveitis, including the launch of its Electro Study, according to a press release. This Phase 2 trial, to be conducted in the U.S., will evaluate the safety and efficacy of the candidate in patients with active forms of all anatomic uveitis subtypes.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The funding will also advance the preclinical development of the firm’s other therapeutic proteins targeting ophthalmic diseases with unaddressed medical needs, such as retinitis pigmentosa and age-related macular degeneration. A product candidate known as EYS606 is currently in a phase I/II clinical trial in the European Union and has been granted an Orphan drug designation by the European Medicines Agency for the treatment of non-infectious uveitis.

The new Series B financing round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance, CapDecisif, and Inserm Transfert, as well as new investors, the Global Health Sciences Fund (Quark Venture LP and GF Securities) and Pureos Bioventures.

In conjunction with the financing, Eyevensys has added members to its board of directors. Neena Kadaba, PhD, director of science at Quark Venture LP, joined the board, as did Dominik Escher, PhD, managing partner at Pureos Bioventures and former founder and CEO of ESBATech, an ophthalmology biotech company acquired by Alcon in 2009.

Eyevensys has also recently opened a wholly owned U.S. subsidiary in Fort Worth, TX. All U.S. operations will be managed from this location, though the Eyevensys headquarters will remain in Paris.

Dr. Patricia Zilliox, Chief Executive Officer, said, “We are thrilled to have completed this Series B funding round with the strong support from both existing and new investors for the company. This funding will assist the further development of our technology and position Eyevensys as an innovator in the field of ophthalmology.”

She continued: “As we launch the Electro Study, our first U.S. clinical trial, Eyevensys will also have an opportunity to connect with ophthalmology opinion leaders in the U.S. to gain further exposure for our groundbreaking technology platform. This will also move the company one step closer to providing a more effective and convenient treatment approach to ease the burden of managing patients with chronic ocular conditions.”

As for technical specifics, the company states:

The Eyevensys technology is a non-viral gene therapy ocular drug delivery platform that uses an Electrotransfection System to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle. This turns the eye into a biofactory, allowing the ciliary muscle to express and secrete the therapeutic protein to the back of the eye at therapeutic levels for a duration of greater than 6 months.

Continue Reading

Headlines

Smart Glasses ‘Breakthrough’ Likely Not Far Off, Zuckerberg Says

New products ‘will redefine our relationship with technology.’

mm

Published

on

Facebook CEO Mark Zuckerberg says major developments in augmented reality are probable in the coming decade, CNBC reports.

He offered his thoughts in a Facebook post last week, writing, “The technology platform of the 2010s was the mobile phone. While I expect phones to still be our primary devices through most of this decade, at some point in the 2020s, we will get breakthrough augmented reality glasses that will redefine our relationship with technology.”

CNBC decribes augmented reality as “technology that lets users place digital objects on top of the real world.”

Zuckerberg acknowledged that some augmented-reality products to this point have felt “clunky.” But he said new products “will be the most human and social technology platforms anyone has built yet.”

He said augmented reality could improve many areas of life, including careers: “Imagine if you could live anywhere you chose and access any job anywhere else. If we deliver on what we’re building, this should be much closer to reality by 2030.”

In September, Facebook was reported to be working with Luxottica to develop a pair of smart glasses. The project was reportedly code-named Orion.

Advertisement

The glasses would be intended to disrupt the smartphone market. Zacks reported at the time that the idea was to “allow users of the smart glasses to take calls, livestream on social media and many other such features that are intended to replace smartphones.”

With the smart glasses project, Facebook was apparently “raising its efforts to withstand the intense competition in the next-generation glasses space from Snap, Google, Microsoft and Apple,” Zacks said at the time.

Read more at the CNBC

Continue Reading

Headlines

$60M to Support Potential Treatment for Eyelash Mite Outbreaks

It could be the ‘first-ever drug treatment for this condition.’

mm

Published

on

IRVINE, CA — Tarsus Pharmaceuticals has announced the completion of $60 million in Series B financing.

The clinical-stage biopharmaceutical company will use the funds to start a Phase 2b/3 trial in the U.S. of its lead product, a drug candidate for treatment of Demodex blepharitis.

An estimated 20 million Americans suffer from blepharitis, and approximately 45 percent of them have clinical signs of Demodex mites, the company explains in a press release. Tarsus is developing a topical ophthalmic that “targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition,” according to the release.

The funding will also fuel Phase 1 and 2 development of other clinical programs. The company’s product pipeline includes additional indications in eyecare and other areas of high unmet clinical need, according to the release.

“We’re excited to support this innovative company that is developing the first drug for Demodex blepharitis and building a pipeline of products to address other large market opportunities,” said Dr. Chen Yu, managing partner at Vivo Capital.

Michael Ackermann, Tarsus chairman, said, “We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine.”

Dr. Bobby Azamian, Tarsus CEO, added, “We are grateful for support from a leading syndicate of healthcare investors. This financing will allow Tarsus to grow, conduct a first registration study in Demodex blepharitis, and broaden our mission to deliver innovative therapies in eye care and beyond by advancing our clinical pipeline in 2020.”

The financing was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group.

 

Continue Reading

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Instagram

This error message is only visible to WordPress admins

Error: API requests are being delayed for this account. New posts will not be retrieved.

There may be an issue with the Instagram Access Token that you are using. Your server might also be unable to connect to Instagram at this time.

Error: No posts found.

Make sure this account has posts available on instagram.com.

Error: admin-ajax.php test was not successful. Some features may not be available.

Please visit this page to troubleshoot.

Most Popular